Neuland Laboratories Limited – Transformation towards niche APIs?

Hi Sir ,Thanks for very prompt response

I went through detailed thread here and Annual Report and recent concall ,Also saw ishmohit sir video on Neuland ,
Basis on that I built scenarios which I am sharing here,

Assumption that I taken into account
1)Sales Growth of 15%, Considering management stating Fy 23 as base year and commercialization of 2 molecules

2)Ebitda margin of 24%,Speciality mix in GDS segment increasing and If Commercialization of two molecules will mean CMS segment share in Revenue pie will increase,Hence overall margin to base Fy23 to increase about 1%

I hope to here from folks who are reading or analysing Neuland

invested,Bias